Immunovant, Inc.
Argenx (ARGX) shares fell 8.7% in pre-market trading after discontinuing a Phase 3 study for futility. Other stocks moving lower include Caribou Biosciences (CRBU), down 3.7% after a downgrade, and several others with declines ranging from 1.8% to 7.4%.
Venker Eric (Chief Executive Officer) sold 3,506 shares of Immunovant, Inc. (IMVT) at $34.11 ($0.12M total) on 2026-10-02.
Venker Eric (Chief Executive Officer) sold (to issuer) 85,886 shares of Immunovant, Inc. (IMVT) at $33.65 ($2.89M total) on 2026-10-01.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning IMVT (Immunovant, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent IMVT coverage spans insider activity, technology and financial news.
In the last 30 days, IMVT insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($3.1M). The most active reporter was Venker Eric, Chief Executive Officer, with 2 filings.
Immunovant dropped 4.8% in pre‑market after the trial miss was disclosed.
Insider sale by the chief executive may signal reduced confidence and could weigh on the stock.
The insider sale may signal reduced confidence from the CEO and could weigh on the stock.
The missed primary endpoint is expected to weigh on IMVT shares.
Insider sale by a senior officer may signal limited confidence, modest negative pressure on the stock.
AlphAI scores every news story that mentions IMVT with an AI model for sentiment and relevance, and aggregates insider trades from Immunovant, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Argenx (ARGX) shares fell 8.7% in pre-market trading after discontinuing a Phase 3 study for futility. Other stocks moving lower include Caribou Biosciences (CRBU), down 3.7% after a downgrade, and several others with declines ranging from 1.8% to 7.4%.
2 min readVenker Eric (Chief Executive Officer) sold 3,506 shares of Immunovant, Inc. (IMVT) at $34.11 ($0.12M total) on 2026-10-02.
1 min readVenker Eric (Chief Executive Officer) sold (to issuer) 85,886 shares of Immunovant, Inc. (IMVT) at $33.65 ($2.89M total) on 2026-10-01.
1 min readImmunovant (IMVT) reported a Phase 2b trial failure for IMVT-1402 in CLE, discontinuing development. Despite missing the primary endpoint, the drug showed positive trends and a favorable safety profile. IMVT-1402 is still being tested in five other autoimmune diseases, with data expected from 2027. The company has $797.8M in cash, and hedge fund interest has increased.
2 min readVan Tuyl Christopher (Chief Legal Officer) sold 2,846 shares of Immunovant, Inc. (IMVT) at $36.36 ($0.10M total) on 2026-09-23.
1 min readRoivant (ROIV) fell premarket after its subsidiary Immunovant (IMVT) reported a failed trial for IMVT-1402, a treatment for cutaneous lupus erythematosus, based on 12-week data.
1 min readImmunovant (IMVT) shares dropped 6% after its lupus drug trial failed to meet the primary endpoint. The study did not show statistical significance in improving CLE symptoms. The company plans to halt development of IMVT-1402 for this indication but will continue trials for other autoimmune diseases. According to Immunovant, the drug showed a favorable safety profile.
2 min readImmunovant, Inc. (IMVT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On September 2, 2026, Immunovant, Inc. ( “ Immunovant ” ) held its 2026 Annual Meeting of Stockholders (the “ Annual Meeting ” ). There were 198,373,370 shares of common stock and Series A preferred stock represented
3 min readGloria Melanie (Chief Operating Officer) sold 3,056 shares of Immunovant, Inc. (IMVT) at $44.16 ($0.13M total) on 2026-08-20.
1 min readImmunovant (IMVT) reported wider Q1 2026 net loss of $153.22M, or $0.75/share, versus $120.61M, or $0.71/share a year earlier. The company cited upcoming pivotal data readouts and potential launches, alongside cash inflows tied to a Moderna settlement. The article also references analyst projections for 2029 revenue and earnings.
5 min read
